HIV 5th Glasgow 2000

Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK

Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy

When should HAART be started?

MDR resistance transmission increases in the UK

Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis

Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)

Clinical issues arising from a single treatment interruption

A review of new anti-HIV drugs in development

Antiretroviral therapy in children, women and intravenous drug users

Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial

Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients

Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART

Child protection issues around starting efavirenz in a mother on maintenance methadone

Structured treatment interruptions

Adherence and HAART: unique approaches to evaluating and improving adherence discussed

Reports on lipodystrophy and metabolic complications

Opportunistic infections in the HAART era